Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 5, 1998, Pages 540-551

  Kashuba, Angela D M ^b   Bertino Jr , Joseph S ^b   Kearns, Gregory L ^b   Leeder, J Steven ^b   James, Alan W ^b   Gotschall, Russell ^b   Nafziger, Anne N ^a  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; CAFFEINE; PHENACETIN O DEETHYLASE; XANTHINE OXIDASE;

ACETYLATOR PHENOTYPE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; GENDER; GENETIC VARIABILITY; HUMAN; MALE; MENSTRUAL CYCLE; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL;

ADULT; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A2; FEMALE; HUMANS; MALE; MENSTRUAL CYCLE; SEX CHARACTERISTICS; XANTHINE OXIDASE;

EID: 0031863228     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90105-9     Document Type: Article

References (40)

1. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
2. Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 1995;27:397-417.
3. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 1994;3:413-21.
4. Kalow W, Tang BK. Use of caffeine metabolic ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991;50:508-19.
5. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992;2:116-27.
6. Weber WW, Hein DW. N-Acetylation pharmacogenetics. Pharmacol Rev 1985;37:25-79.
7. Evans DAP. N-Acetyltransferase. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press; 1992. p. 95-178.
8. Clark DWJ. Genetically determined variability in acetylation and oxidation: therapeutic implications. Drugs 1985;29:342-75.
9. Lunde PKM, Frislid K, Hansteen V. Disease and acetylation polymorphism. Clin Pharmacokinet 1977; 2:182-97.
10. Kalow W. Ethnic differences in drug metabolism. Clin Pharmacokinet 1982;7:373-400.
11. Drayer DE, Reidenberg MM. Clinical consequences of polymorphic acetylation of basic drugs. Clin Pharmacol Ther 1977;22:251-8.
12. Cartwright RA, Glasham RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, et al. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982;2:842-6.
13. Hein DW. Genetic polymorphism and cancer susceptibility: evidence concerning acetyltransferases and cancer of the urinary bladder. Bioessays 1988;9:200-4.
14. Kretnitsky TA, Tuttle JV, Cattau EL, Wang P. A comparison of the distribution and electron acceptor specificities of xanthine oxidase and aldehyde oxidase. Comp Biochem Physiol 1974;49B:687-703.
15. Kalow W. Variability of caffeine metabolism in humans. Drug Res 1985;35:319-24.
16. Guerciolini R, Szumlanski C, Weinshilboum RM. Human liver xanthine oxidase: nature and extent of individual variation. Clin Pharmacol Ther 1991;50:663-72.
17. Campell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987;42:157-65.
18. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984;17:459-64.
19. Grant DM, Tang BK, Campbell ME, Kalow W. Effect of allopurinol on caffeine disposition in man. Br J Clin Pharmacol 1986:21:454-8.
20. Food and Drug Administration. Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs. Federal Register 1993;58:39406-16.
21. Wilson K. Sex related differences in drug disposition in man. Clin Pharmacokinet 1984;9:189-202.
22. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50:222-39.
23. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992;52:643-58.
24. Horn EP, Tucker MA, Lambert G, Silverman D, Zametkin D, Sinha R, et al. A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. Cancer Epidemiol Biomarkers Prev 1995;4:529-33.
25. Bartoli A, Xiaodong S, Gatti G, Cipolla G, Marchiselli R, Perucca E. The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. Ther Drug Monit 1996;18:586-91.
26. Lane JD, Steege JF, Rupp SL, Kühn CM. Menstrual cycle effects on caffeine elimination in the human female. Eur J Clin Pharmacol 1992;43:543-6.
27. Bruguerolle B, Toumi M, Faraj F, Vervloet D, Razzouk H. Influence of the menstrual cycle on theophylline pharmacokinetics in asthmatics. Eur J Clin Pharmacol 1990;39:59-61.
28. Wojciki J, Gawronska-Szklarz B, Kazimierczyk J, Baskiewicz Z, Raczynski A. Comparative pharmacokinetics of paracetamol in men and women considering follicular and luteal phases. Arzneimittelforschung 1979;29: 350-2.
29. Paulsen O, Nilsson LG. Distribution of acetylator phenotype in relation to age and sex in Swedish patients. Eur J Clin Pharmacol 1985;28:311-5.
30. Philip PA, Gayed SL, Rogers HJ, Crome P. Influence of age, sex and body weight on the dapsone acetylation phenotype. Br J Clin Pharmacol 1987;23:709-13.
31. Korrapati MR, Sorkin JD, Andres R, Muller CD, Loe C, Vesell ES, et al. Acetylator phenotype in relation to age and gender in the Baltimore longitudinal study of aging. J Clin Pharmacol 1997;37:83-91.
32. Tang KB, Zhou Y, Kadar D, Kalow W. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 1994;4:117-24.
33. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 1981;2:93-113.
34. Evans WH, Relling MV, Petros WP, Meyer WH, Mirro J Jr, Crom WR. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 1989;45:568-73.
35. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983;33:591-602.
36. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991;49:648-57.
37. SYSTAT user's guide. Evanston (IL): SYSTAT Intelligent Software; 1990.
38. Devine BJ. Gentamicin pharmacokinetics. Drug Intell Clin Pharm 1974;8:650-5.
39. Cockcroft DW, Gault MDH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
40. Okey AB. Enzyme induction in the cytochrome P-450 system. Pharmacol Ther 1990;45:241-98.